Tree of Knowledge International Corp. (CSE:TOKI; OTC:TRKWF) (the “Company” or “TOK”) (formerly Courtland Capital Inc.) is pleased to announce it has entered into a distribution agreement with Dr. Sanjay Gupta (the “Agreement”).

Tree of Knowledge International Corp. (CSE:TOKI; OTC:TRKWF) (the “Company” or “TOK”) (formerly Courtland Capital Inc.) is pleased to announce it has entered into a distribution agreement with Dr. Sanjay Gupta (the “Agreement”). Dr. Gupta, one of the most well-known medical professionals worldwide, joined the advisory board of TOK in July (see press release July 18, 2018). Through his work as President of the American Pain Association and other notable appointments he has access to a network of more than 160,000 medical professionals.

Pursuant to the Agreement, TOK will provide expertise in preparing formulations, manufacturing, production, inspection and packaging of a line of CBD and cannabis products for Dr. Gupta, as well as assist Dr. Gupta with labeling the products under Dr. Gupta’s name (the “Gupta Products”). In addition, the Company will assist with product sales and distribution. The new product line, branded under the name “Dr. Gupta’s” will include numerous products including, but not limited to, Premium Hemp Oil – CBD Capsules, CBD Tincture and CBD Salve. These premium products will be non-GMO and gluten-free. Under the Agreement, Dr. Gupta will own all the intellectual property associated with the Gupta Products, except for specific formulations prepared by TOK. The Agreement is for an initial term of two years and will automatically renew for successive additional one year periods so long as certain sales criteria are met.

Jean-Paul Gaillard, CEO of the Company stated: “We are extremely excited that Dr. Gupta has selected TOK to work with to create a new product line under his name. We see this as an extraordinary partnership where we can combine our expertise in creating premium quality products with Dr. Gupta’s worldwide name recognition. This is an important addition to our product pipeline. Dr. Gupta’s global reach includes an extensive network of physicians, patients and followers.”

Dr. Sanjay Gupta stated: “As the world perception is changing with respect to CBD products, I have embraced Tree of Knowledge, first as an advisory member and now as a product partner. Their vigorous testing and the exceptional quality of their products, being free of pesticides and microbial, makes them a world leader. This level of quality allows me to offer my network of top medical professionals a line of products that they can be completely comfortable in recommending to their patients.”

ABOUT TREE OF KNOWLEDGE

The Company produces and sells hemp-based cannabidiol (‘CBD”) products in certain jurisdictions in the United States, as well as in Europe, South America, Australia and China. Cannabidiol/CBD is a natural constituent of hemp which is purported to contain wellness properties. TOK’s CBD product line contains EVR Premium Hemp Oil, which is an organically grown and handled, gluten-free, vegan, non-GMO, synergistic compound that is derived from U.S. Department of Agriculture (USDA) approved industrial hemp grown in the United States. TOK currently offers several CBD products, which may be used in connection with the treatment of a number of ailments and for general wellness purposes.

For further information about TOK, please see the Company’s website at www.Evrcbd.com or contact the following:

Tree of Knowledge International Corp.

Michael Caridi, Chairman and CEO or

Tel: +1 (917) 295-1374

Michael@evrcbc.com

Daniel Caridi

Assistant to the Chairman

+1 (203) 969-5678

Daniel@evrcbd.com

Rahim Rajwani

Partner/Founder/Head of Compliance and Risk

Northbay Capital Partners Corp.

Suite 918-1030 West Georgia Street Vancouver, BC V6E 2Y3

M: 604.376.8821

T: 604.628.2661

www.northbaycapitalpartners.com

THE CSE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE.

Forward Looking Statements

This news release contains forward-looking statements relating to the proposed relationship between the Company and Dr. Gupta pursuant to the Agreement. There is no assurance that the product line will be successful or whether TOK will be able to realize all the expected benefits therefrom. These forward looking statements involve risks and uncertainties. Events or circumstances may cause actual results to differ materially from those anticipated as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company or the parties to the Agreement. These include legal and regulatory changes, the impact of general economic, industry and market conditions; expectations regarding market demand for particular products; the risks associated with product development and the impact of product competition. As a result, the Company cannot guarantee that any forward-looking statement will materialize and the reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by Management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and Management of the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable securities laws.

Featured
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. for violations of the securities lawsThe investigation focuses on whether the Company issued false andor misleading statements andor failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the ...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or "the Company") (NASDAQ:CRON) for violations of the securities laws

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cronos filed a Form 8-K with the SEC on November 9, 2021, disclosing that the Company would "be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021" and that "the Company's financial statements for this period should therefore no longer be relied upon." Based on this news, shares of Cronos fell by nearly 16%.

read more Show less
Florida's leading medical cannabis company to open its 110 th dispensary in the state, invites Tampa community to join ribbon cutting and grand opening celebration Trulieve Cannabis Corp. a leading and top-performing cannabis company in the United States today announced the opening of its newest dispensary located on North Dale Mabry Highway in Tampa, Florida . Trulieve will host a ribbon cutting and begin serving ...

Florida's leading medical cannabis company to open its 110 th dispensary in the state, invites Tampa community to join ribbon cutting and grand opening celebration

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of its newest dispensary located on North Dale Mabry Highway in Tampa, Florida . Trulieve will host a ribbon cutting and begin serving patients at this location at 9:00 am on Thursday, December 2 and will continue the celebration with all-day festivities and deals. The new location is Trulieve's 110 th dispensary in Florida and its 157 th nationwide.

read more Show less
Now in Ten States, B NOBLE Partnership Advances Social Equity in Cannabis and Provides Opportunity to Those Directly Impacted by the War on Drugs B NOBLE Inc. and Curaleaf, a leading international provider of consumer products in cannabis, today announced the expansion of its B NOBLE partnership into medical dispensary locations in New York . This expansion is one of the first partnerships of its kind in New York as ...

Now in Ten States, B NOBLE Partnership Advances Social Equity in Cannabis and Provides Opportunity to Those Directly Impacted by the War on Drugs

B NOBLE Inc. and Curaleaf, a leading international provider of consumer products in cannabis, today announced the expansion of its B NOBLE partnership into medical dispensary locations in New York . This expansion is one of the first partnerships of its kind in New York as the New York Cannabis Control Board recently approved whole flower as part of its medical marijuana offerings in late October.

read more Show less

MARKETS

Markets
TSX20464.60-195.39
TSXV917.92-21.52
DOW34022.04-461.68
S&P 5004513.04-53.96
NASD15254.05-283.64
ASX7235.90-20.10

COMMODITIES

Commodities
Gold1776.15-5.67
Silver22.360.00
Copper4.27+0.02
Palladium1762.00+11.00
Platinum943.50+7.50
Oil66.33+0.76
Heating Oil2.09+0.02
Natural Gas4.26+0.01